Catalyst Pharmaceuticals (CPRX) Capital Expenditures (2011 - 2026)

Catalyst Pharmaceuticals has reported Capital Expenditures for 13 years, with the latest figure at $27000.0 in Q1 2026.

• For the quarter ending Q1 2026, Capital Expenditures changed N/A year-over-year to $27000.0; the trailing twelve-month figure through Mar 2026 stood at $85000.0 (down 76.19% YoY), and the FY2025 full-year result was $58000.0, down 89.57% from the prior year.
• Capital Expenditures for Q1 2026 stood at $27000.0, down from $32000.0 in the prior quarter.
• The five-year high for Capital Expenditures was $259000.0 in Q3 2024, with the low at $10000.0 in Q2 2024.
• Historically, Capital Expenditures has averaged $87200.0 across 4 years, with a median of $69000.0 in 2023.
• Annual changes were most pronounced in 2024 — Capital Expenditures jumped 304.69% — and 2025, when it tumbled 63.64%.
• Catalyst Pharmaceuticals' Capital Expenditures stood at $93000.0 in 2023, then decreased by 5.38% to $88000.0 in 2024, then plunged by 63.64% to $32000.0 in 2025, then dropped by 15.62% to $27000.0 in 2026.
• The last three Capital Expenditures figures came in at $27000.0 (Q1 2026), $32000.0 (Q4 2025), and $26000.0 (Q2 2025), per Business Quant data.